Paper Details

  1. Home
  2. Paper Details

A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism.

Author: AldersonHelen, BubtanaAbdalla, ChinnaduraiRajkumar, ChrysochouConstantina, EddingtonHelen, ErekosimaIbi, GreenDarren, HegartyJanet, HutchisonAlastair, IbrahimSara T, KalraPhilip A

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

An open-label prospective randomized controlled trial of 36 haemodialysis patients with secondary hyperparathyroidism found no significant benefit in bone and cardiovascular markers with the addition of cinacalcet to standard therapy over one year. However, tight control of hyperphosphataemia and secondary hyperparathyroidism may lead to a reduction in left ventricular mass index and carotid intima-media thickness, but this needs further investigation.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control. METHODS: This is an open-label prospective randomised controlled trial to compare progression...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989372/

データ提供：米国国立医学図書館（NLM）

Cinacalcet and Bone and Cardiovascular Health: A Desert Oasis of Insights in Dialysis

Secondary hyperparathyroidism is a common complication in patients on dialysis, posing a significant risk to bone and cardiovascular health. This study investigates the effects of cinacalcet, a medication used to lower parathyroid hormone (PTH) levels, on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. Researchers meticulously analyzed data from patients who received cinacalcet in addition to standard therapy or standard therapy alone. The study found that cinacalcet did not significantly improve bone or cardiovascular markers over one year, suggesting that intensive management of CKD-MBD parameters may be sufficient for achieving desired outcomes. This research provides valuable insights into the complex interplay of PTH, phosphate, and cardiovascular health in dialysis patients.

Cinacalcet: A Well-Stocked Oasis in the Desert of Dialysis

This study highlights the importance of intensive management of CKD-MBD parameters in haemodialysis patients. The research, like a well-stocked oasis in the vast desert of dialysis care, provides valuable insights into the potential benefits and limitations of cinacalcet in managing secondary hyperparathyroidism. The findings suggest that a multidisciplinary approach to managing CKD-MBD, involving nephrologists, endocrinologists, and cardiologists, is essential for optimizing patient outcomes. This study underscores the importance of ongoing research to develop personalized treatment strategies tailored to individual patient needs.

Navigating the Desert of Dialysis: A Journey of Health

This study emphasizes the importance of comprehensive management of CKD-MBD in dialysis patients. The research highlights the complex interplay of various factors, including PTH, phosphate, and cardiovascular health, and encourages a collaborative approach to optimizing patient outcomes. This study provides a roadmap for healthcare professionals, encouraging a personalized and holistic approach to managing dialysis patients.

Dr.Camel's Conclusion

This study provides a valuable oasis in the desert of dialysis research, offering insights into the potential benefits and limitations of cinacalcet in managing secondary hyperparathyroidism in haemodialysis patients.

Date :
  1. Date Completed 2022-02-07
  2. Date Revised 2022-02-07
Further Info :

Pubmed ID

33757437

DOI: Digital Object Identifier

PMC7989372

Related Literature

Article Analysis
・Effects of cinacalcet
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.